Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ibuprofen + ondansetron is a combination drug regimen being evaluated by Hackensack Meridian Health for the management of side effects associated with medical abortion. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that acts by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing prostaglandin synthesis to alleviate pain and inflammation. Ondansetron is a selective 5-HT3 receptor antagonist that prevents nausea and vomiting by blocking serotonin receptors in the gastrointestinal tract and the chemoreceptor trigger zone. The combination is specifically studied as a prophylactic regimen to improve patient satisfaction and reduce the incidence of pain and nausea following misoprostol administration in patients undergoing medical abortion at less than 70 days of gestation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + ondansetron.